Ovarian cancer statistics, 2018

May 29, 2018, American Cancer Society
Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left - diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. Credit: Nephron /Wikipedia. CC BY-SA 3.0

A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data. Ovarian Cancer Statistics, 2018 is published early online in CA: A Cancer Journal for Clinicians.

Below are highlights from the report.

  • In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States.
  • In the U.S., overall ovarian cancer incidence declined by 29% from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000), while mortality declined 33% from 1976 (10.0 per 100,000) to 2015 (6.7 per 100,000).
  • Decreases in ovarian cancer incidence has been driven largely by declines in whites that accelerated during the past decade.
  • Racial/ethnic differences in ovarian cancer risk are partially explained by known risk factors. Multiple births, use of , tubal ligation, and oophorectomy reduce risk, while menopausal hormone use increases risk. However, the source of most of the variation remains unknown.
  • Declines in ovarian cancer mortality are due to reductions in incidence as well as improvements in treatment.
  • The strongest risk factor for ovarian cancer is a family history of breast or ovarian cancer.
  • Mutations in BRCA1 and BRCA2 account for almost 40% of ovarian cancer cases in with a family history of the disease.
  • Due to a relatively high prevalence of identified genetic mutations, genetic testing is recommended for all women diagnosed with ovarian cancer to inform their medical and reproductive decisions and those of their relatives.
  • Incidence of ovarian cancer among women over 65 has generally declined at a continuous rate since at least 1975, likely due to uptake of oral contraceptives, which confer a substantial risk reduction and also likely contributed to the recent declines in older women.
  • Among women who use oral contraceptives for five to nine years total, risk is reduced by about 35%.
  • Currently, there is no recommended screening test for ovarian cancer, although large scale randomized clinical studies to identify effective screening modalities are ongoing.
  • The efficacy of screening for ovarian cancer has not been demonstrated in prospective randomized controlled trials.
  • Studies indicate that some women experience persistent nonspecific symptoms in the months prior to diagnosis, including back pain, abdominal distension, pelvic or abdominal pain, difficulty eating or feeling full quickly, vomiting, indigestion, altered bowel habits, or urinary urgency or frequency. Women who experience such symptoms daily for more than a few weeks should seek prompt medical evaluation.

"Although ovarian cancer is not one of the most common cancers, it causes 5 percent of deaths among US women," said Lindsey Torre, MSPH, lead author of the report. "Understanding of the disease has evolved rapidly in recent years; however, much remains to be gained in research."

Explore further: Ovarian cancer is hard to detect

More information: Ovarian Cancer Statistics, 2018, CA: A Cancer J for Clin, onlinelibrary.wiley.com/doi/fu … l/10.3322/caac.21456

Related Stories

Ovarian cancer is hard to detect

May 12, 2018
Ovarian cancer is estimated to affect more than 22,000 women each year and is the fifth leading cause of cancer deaths among women, according to American Cancer Society.

USPSTF recommends against ovarian cancer screening

February 13, 2018
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer in asymptomatic women. These findings form the basis of a final recommendation statement published in the Feb. ...

No link found for metformin or statins and ovarian cancer

February 27, 2018
(HealthDay)—In women with type 2 diabetes, no evidence was found of an association between the use of metformin or statins and the incidence of ovarian cancer, according to a study published online Feb. 7 in BJOG: An International ...

New ovarian cancer drug licensed for use

December 21, 2017
A new drug to delay the spread of ovarian cancer, which was developed from UCL research, has been licensed for use in the UK.

Know the risks, warning signs of ovarian cancer

January 19, 2017
(HealthDay)—Women need to be aware their risk for ovarian cancer increases with age. Half of all cases affect women age 63 or older, according to specialists at Fox Chase Cancer Center in Philadelphia.

FDA warns ovarian cancer tests not reliable

September 9, 2016
(HealthDay)—Screening tests for ovarian cancer are not reliable and should not be used, the U.S. Food and Drug Administration warns.

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.